Deal Watch: Xencor Adds New Bispecific Partner In Agreement With Genentech

 
• By Joseph Haas and Jung Won Shin

Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.

DealWatch_1200x675

More from Deals

More from Business